Several HDAC inhibitors have been approved by United States Food and Drug Administration (FDA) for the treatment of patients with cutaneous and peripheral T-cell lymphoma, and are undergoing clinical trials for the treatment of solid tumors and leukemia. Here, HDAC9 is linked to leukemia.